Discrepancy in transcriptomic profiling between CD34 + stem cells and primary bone marrow cells in myelodysplastic...

Area of Science:

• Genomics
• Molecular Biology
• Hematology

Background:

• Myelodysplastic Neoplasms (MDS) are complex hematologic disorders.
• Identifying reliable biomarkers for MDS diagnosis and treatment is challenging.
• Understanding gene expression differences in key cell types is crucial for MDS pathogenesis.

Discussion:

• This study performed an in-silico transcriptome analysis of CD34+ HSC and PBMC from 1092 MDS patients.
• It investigated the divergences in differential gene expression patterns between these two cell types.
• The analysis aimed to identify potential pathogenic biomarkers for MDS.

Key Insights:

• A significant difference of 7117 expressed transcripts was observed between PBMC and CD34+ HSC.
• 240 DEGs were identified in CD34+ HSC, while 2948 DEGs were found in PBMC.
• Despite disparities, both cell types showed similarities in activated pathways via Gene Ontology and KEGG analyses.

Outlook:

• The findings offer novel insights into DEGs biomarkers for MDS pathogenesis.
• These biomarkers may have clinical significance for MDS diagnosis and monitoring.
• Further research can explore the functional roles of these identified DEGs in MDS progression.